The university of chicago
Center for Personalized Therapeutics
By making pharmacogenomic information prompt, accessible, and understandable for physicians, The Center for Personalized Therapeutics (CPT) leads the way in translating genomic discovery to improve care for patients.
Projects
CPT conducts clinical trials in diverse medical fields, including perioperative, oncology, in-patient, out-patient, and beyond.
Research
CPT leads exceptional research on translational genomic discoveries and pharmocogenomics.
Training + Career
CPT offers career and research opportunities for undergraduate, graduate, and post-doctoral trainees.
Collaboration
CPT partners with other departments and specialties to advance our understanding of the human genome.
Explore our Program
In 2000 the first draft sequence of the human genome was released, and widespread use of techniques to implement and translate such genomic knowledge was slow to be adopted by the medical community. In 2009, the future leadership of the CPT felt that there was a critical mass of information regarding the association of individual genetic variability with drug-related adverse event and response outcomes and therefore established the Center.
Dedication to Precision Health Care
In 2000 the first draft sequence of the human genome was released, and widespread use of techniques to implement and translate such genomic knowledge was slow to be adopted by the medical community. In 2009, the future leadership of the CPT felt that there was a critical mass of information regarding the association of individual genetic variability with drug-related adverse event and response outcomes and therefore established the Center.
The Center embarked on its first project in 2011, the 1200 Patients Project, which uses a preemptive ‘medical system model’ for personalized care that makes relevant pharmacogenomic information instantaneously accessible at the time of prescribing to reduce the use of inapprorpiate and high risk medications in patients for whom pharmacogenomic results are known, thereby decreasing adverse events and non-responsive rates.
Leader in Personalized Therapeutics
Total providers enrolled in the US
Providers enrolled in the ImPreSS Trial
Providers enrolled in the ACCOuNT Project
Projects
The Center is uniquely positioned to further enhance collaborative clinical, research and training efforts in partnership with other departments and units of the university.
Collaboration
The CPT interfaces and collaborates with a number of existing units including: the Departments of Medicine (Sections of Genetic Medicine, Hematology/Oncology, General Internal Medicine, and Hospital Medicine), Pathology, Human Genetics, and Health Studies; the Committee on Clinical Pharmacology and Pharmacogenomics; the Comprehensive Cancer Center; the Center for Health and the Social Sciences; the MacClean Center for Clinical Medical Ethics; and the Institute for Genomics and Systems Biology. These interactions are vital to the CPT’s mission and ultimate goals.
Translating Genomic Discovery to Therapeutics
Our Goal
One of the key goals of the Center is to develop systems for efficient collection, storage and clinical application of genetic data and to train physicians in the use of personalized genetic information as tools in patient care which can help identify the patients most likely to respond to, or be harmed by, specific therapies.
Our Approach
Current CPT reserach focuses on the evaluation of pharmacogenomics markers in the context of clinical trials at all phases of drug development. In addition, researchers are working in the area of new drug development by using genomic research findings to identify new targets, leading to the development of antibodies, peptide vaccines, and small molecular compounds.
In the near future, the Center plans to expand the availability of pre-emptive clinical testing for use in additional patient populations at a variety of institutions around the counry. The ultimate goal of the Center is to develop innovative, personalized and effective therapies for all patients.
Personalized Therapeutics Clinic
The purpose of the Personalized Therapeutics Clinic is to provide expert consultative input from a Clinical Pharmacologist regarding medication issues. Examples include complex issues concerning pharmacogenomics, polypharmacy, drug-drug interactions, drug-food interactions, drug-herbal interactions, and dosing in the context of organ dysfunction.
We are recruiting for a clinical study named, “Evaluating the Effectiveness of a Personalized Therapeutics Clinic on Drug-Drug and Drug-Gene Interactions,” or the “Personalized Therapeutics Study” for short, which combines the use of pharmacogenomics with the establishment of the novel Personalized Therapeutics Clinic at UChicago Medicine. Participants in this study ultimately have the opportunity to undergo genetic testing and have subsequent results analyzed to determine potentially-adverse drug-drug interactions (DDIs) and drug-gene interactions (DGIs).
For those participants whose DNA is genetically tested, they also have the opportunity to attend a virtual appointment(s) with a healthcare provider from the PTC who will discuss with participants the pharmacogenomic results and their implications.
Developing Effective Therapies for All
The mission of the Optimal Cancer Care Alliance (OCCA) is to ensure that each patient receives the optimal dosage of the medications needed to effectively treat their cancer.
2023 Optimal Cancer Care Alliance
This year, OCCA’s annual meeting is on the afternoon of September 11th and the morning of September 12th (North American Eastern time) and will include one or more invited presentations, as well as oral presentations (10 minutes) of selected submitted abstracts.
